Nurix legal chief sells 5,387 shares, exercises options

Q: What insider transactions did NRIX’s Chief Legal Officer report on September 2, 2026?

The Chief Legal Officer exercised options for 5,787 shares of Nurix Therapeutics common stock at $8.72 per share and sold 5,387 shares at a weighted average of $25.6947 and 400 shares at a weighted average of $26.6375, all on September 2, 2026.

Q: How many Nurix Therapeutics (NRIX) options does the insider retain after these transactions?

After exercising options for 5,787 shares on September 2, 2026, the reporting person holds 117,037 employee stock options from the referenced grant, according to the filing.

Q: What prices were NRIX shares sold for in the reported insider sales?

The filing reports sales of 5,387 shares at a weighted average price of $25.6947 per share, with individual prices between $25.41 and $26.23, and 400 shares at a weighted average of $26.6375 per share, with individual prices between $26.46 and $26.73.

Q: What are the key terms of the NRIX stock option exercised by the insider?

The employee stock option has an exercise price of $8.72 per share, vests as to one thirty-sixth of the total shares monthly beginning March 13, 2024, and is scheduled to be fully vested by February 13, 2027, with an expiration date of February 12, 2034.

Nurix Therapeutics’ chief legal officer exercised options and sold 5,787 NRIX shares under a pre-set Rule 10b5-1 trading plan.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) reported that Chief Legal Officer Christine Ring exercised employee stock options for 5,787 shares of common stock on September 2, 2026 at an exercise price of $8.72 per share, converting them into common stock. These options were part of a grant vesting monthly from March 13, 2024 until February 13, 2027, and following this exercise 117,037 options remain outstanding from the grant. On the same date, she sold 5,387 shares of common stock at a weighted average price of $25.6947 per share and 400 shares at a weighted average price of $26.6375 per share, in each case in transactions carried out under a previously adopted Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 5,787 shares ($99K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 5,787 shs ($149K)

Approx. gross sale proceeds $149K

Approx. exercise cost $50K

Approx. pre-tax spread $99K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) ^{F1, F4}	5,787	$0.00	$0.00
Exercise	Common Stock ^F1	5,787	$8.72	$50K
Sale	Common Stock ^{F1, F2}	5,387	$25.6947	$138K
Sale	Common Stock ^{F1, F3}	400	$26.6375	$11K

Holdings After Transaction: Employee Stock Option (right to buy) — 117,037 contracts (Direct); Common Stock — 9,110 shares (Direct)

Footnotes (4)

F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2. Represents the weighted average sale price. The lowest price at which shares were sold was $25.41 and the highest price at which shares were sold was $26.23. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3. Represents the weighted average sale price. The lowest price at which shares were sold was $26.46 and the highest price at which shares were sold was $26.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F4. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Options exercised: 5,787 shares Option exercise price: $8.72 per share Shares sold (block 1): 5,387 shares +5 more

8 metrics

Options exercised 5,787 shares Employee stock options converted into common stock on September 2, 2026

Option exercise price $8.72 per share Exercise price for the 5,787 options exercised on September 2, 2026

Shares sold (block 1) 5,387 shares Common stock sold on September 2, 2026 at a weighted average of $25.6947

Weighted average sale price (block 1) $25.6947 per share 5,387 shares sold; individual prices between $25.41 and $26.23

Shares sold (block 2) 400 shares Common stock sold on September 2, 2026 at a weighted average of $26.6375

Weighted average sale price (block 2) $26.6375 per share 400 shares sold; individual prices between $26.46 and $26.73

Remaining options from grant 117,037 options Employee stock options remaining after the reported exercise

Option expiration date February 12, 2034 Expiration date of the employee stock option grant exercised in part

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, employee stock option, vests

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price. The lowest price at which shares were sold"

employee stock option financial

"The stock option vests as to 1/36 of the total shares monthly"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

vests financial

"The stock option vests as to 1/36 of the total shares monthly"

FAQ

What insider transactions did NRIX’s Chief Legal Officer report on September 2, 2026?

The Chief Legal Officer exercised options for 5,787 shares of Nurix Therapeutics common stock at $8.72 per share and sold 5,387 shares at a weighted average of $25.6947 and 400 shares at a weighted average of $26.6375, all on September 2, 2026.

Were the NRIX insider trades made under a Rule 10b5-1 trading plan?

Yes. The filing states that the reported transactions were effected pursuant to a previously adopted Rule 10b5-1 trading plan by the reporting person.

How many Nurix Therapeutics (NRIX) options does the insider retain after these transactions?

After exercising options for 5,787 shares on September 2, 2026, the reporting person holds 117,037 employee stock options from the referenced grant, according to the filing.

What prices were NRIX shares sold for in the reported insider sales?

The filing reports sales of 5,387 shares at a weighted average price of $25.6947 per share, with individual prices between $25.41 and $26.23, and 400 shares at a weighted average of $26.6375 per share, with individual prices between $26.46 and $26.73.

What are the key terms of the NRIX stock option exercised by the insider?

The employee stock option has an exercise price of $8.72 per share, vests as to one thirty-sixth of the total shares monthly beginning March 13, 2024, and is scheduled to be fully vested by February 13, 2027, with an expiration date of February 12, 2034.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 07:43 PM Accepted by SEC EDGAR 09/02/2026 - 07:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/02/2026		M⁽¹⁾		5,787	A	$8.72	14,897	D
Common Stock	09/02/2026		S⁽¹⁾		5,387	D	$25.6947⁽²⁾	9,510	D
Common Stock	09/02/2026		S⁽¹⁾		400	D	$26.6375⁽³⁾	9,110	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$8.72	09/02/2026		M⁽¹⁾			5,787	⁽⁴⁾	02/12/2034	Common Stock	5,787	$0	117,037	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $25.41 and the highest price at which shares were sold was $26.23. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Represents the weighted average sale price. The lowest price at which shares were sold was $26.46 and the highest price at which shares were sold was $26.73. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

4. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR